Page last updated: 2024-08-25

rosiglitazone and n-desmethylrosiglitazone

rosiglitazone has been researched along with n-desmethylrosiglitazone in 5 studies

Research

Studies (5)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (60.00)	29.6817
2010's	2 (40.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Backman, JT; Granfors, M; Laitila, J; Neuvonen, M; Neuvonen, PJ; Niemi, M	1
Ha, JM; Kim, HK; Kim, KA; Park, JY; Park, PW	1
Mullangi, R; Muzeeb, S; Srinivas, NR; Venkatesh, P	1
McLean, L; Naik, H; Palmer, R; Wu, JT	1
Cutler, DL; Hanson, ME; Kantesaria, B; Kosoglou, T; Kumar, B; Schiller, JE; Sisk, CM; Statkevich, P	1

Trials

4 trial(s) available for rosiglitazone and n-desmethylrosiglitazone

Article	Year
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia, 2003, Volume: 46, Issue:10 Topics: Adult; Area Under Curve; Cross-Over Studies; Female; Gemfibrozil; Half-Life; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Osmolar Concentration; Rosiglitazone; Thiazolidinediones; Time Factors	2003
Effect of quercetin on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in healthy subjects. Journal of clinical pharmacology, 2005, Volume: 45, Issue:8 Topics: Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C8; Half-Life; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Quercetin; Rosiglitazone; Thiazolidinediones	2005
The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrate. British journal of clinical pharmacology, 2012, Volume: 74, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Analysis of Variance; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Biotransformation; Cross-Over Studies; Cytochrome P-450 CYP2C8; Double-Blind Method; Drug Interactions; Febuxostat; Female; Gout Suppressants; Half-Life; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Rosiglitazone; Substrate Specificity; Thiazoles; Thiazolidinediones; Young Adult	2012
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics of rosiglitazone. Clinical pharmacology in drug development, 2015, Volume: 4, Issue:1 Topics: Adolescent; Adult; Area Under Curve; Biotransformation; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Drug Interactions; Female; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Lactones; Male; Metabolic Clearance Rate; Middle Aged; North Dakota; Platelet Aggregation Inhibitors; Pyridines; Receptor, PAR-1; Rosiglitazone; Therapeutic Equivalency; Thiazolidinediones; Young Adult	2015

Other Studies

1 other study(ies) available for rosiglitazone and n-desmethylrosiglitazone

Article	Year
Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats. Xenobiotica; the fate of foreign compounds in biological systems, 2006, Volume: 36, Issue:9 Topics: Administration, Oral; Animals; Anticholesteremic Agents; Biological Availability; Cholestyramine Resin; Chromatography, High Pressure Liquid; Drug Interactions; Hydrogen-Ion Concentration; Hypoglycemic Agents; Injections, Intravenous; Kinetics; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Time Factors	2006

Article

Year

Influence of cholestyramine on the pharmacokinetics of rosiglitazone and its metabolite, desmethylrosiglitazone, after oral and intravenous dosing of rosiglitazone: impact on oral bioavailability, absorption, and metabolic disposition in rats.

Xenobiotica; the fate of foreign compounds in biological systems, 2006, Volume: 36, Issue:9

Topics: Administration, Oral; Animals; Anticholesteremic Agents; Biological Availability; Cholestyramine Resin; Chromatography, High Pressure Liquid; Drug Interactions; Hydrogen-Ion Concentration; Hypoglycemic Agents; Injections, Intravenous; Kinetics; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Time Factors

2006